89bio, Inc. (NasdaqGM: ETNB)
Health Care · Biotechnology · US
$—
— today · — 1Y
89bio, Inc. (NasdaqGM: ETNB) operates in the Biotechnology industry within the Health Care sector.
trading between 14.77 and 14.87.
Tweenvest scores 89bio, Inc. across four factors: quality 38/100, value 66/100. Its strongest factor is value.
ETNB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.41
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $14.87
- 52-week low
- $14.77
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 93
- Next earnings
- —
About 89bio, Inc.
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.
- ISIN
- US2825591033
- Founded
- 2018
- Listed since
- Nov 11, 2019
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PhaseRx, Inc.OTCPK: PZRX.Q | $12.00 | $— | — |
| ContraFect CorporationOTCPK: CFRX.Q | $11.00 | $0.00 | — |
| Notable Labs, Ltd.OTCPK: NTBL.Q | $10.00 | $— | — |
| OncoSec Medical IncorporatedOTCPK: ONCS.Q | $6.00 | $0.00 | — |
| Calithera Biosciences, Inc.OTCPK: CALA | $5.00 | $0.00 | -99.00% |
| Biocept, Inc.OTCPK: BIOC.Q | $3.00 | $0.00 | -99.50% |
| Yield10 Bioscience, Inc.OTCPK: YTEN.Q | $1.00 | $— | — |
| LadRx CorporationOTCPK: LADX | $0.00 | $0.00 | -99.50% |
Figures last refreshed Oct 18, 2026.